Hemogenyx Pharmaceuticals Plc

Equities

SILF

GB00BYX3WZ24

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:10 2024-04-26 am EDT			5-day change	1st Jan Change
1.65 ^GBX	+4.10%		+0.55%	-28.26%

Apr. 25	EARNINGS: LSL starts 2024 "strongly"; Focusrite maintains payout	AN
Apr. 25	Hemogenyx Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Hemogenyx Pharmaceuticals achieves breakthrough with HEMO-CAR-T program, CBR platform

February 20, 2024 at 08:10 am EST

(via NewsDirect)

Hemogenyx Pharmaceuticals PLC CEO Dr Vladislav Sandler and non-executive director Peter Redmond joined Proactive's Stephen Gunnion after the company pioneering breakthrough treatments for life-threatening diseases, including blood and solid cancers, achieved a number of significant milestones.

Sandler highlighted the company's significant progress with its HEMO-CAR-T program after it received the green light from the US Food and Drug Administration (FDA) to enter Phase 1 clinical trials for acute myeloid leukaemia, marking its transition to a clinical-stage biopharmaceutical company. This development symbolises a pivotal milestone, offering potential life-changing treatments for patients with limited options.

Additionally, Hemogenyx is advancing its proprietary Chimeric Bait Receptor (CBR) platform, announcing that it has demonstrated in vivo that the CBR can be delivered intranasally in the form of messenger RNA (mRNA) for the potential treatment of airborne viral infections.

As 2024 unfolds, Hemogenyx anticipates starting clinical trials and advancing its CBR platform towards IND-enabling studies, signaling a landmark year with promising outcomes for investors and patients alike.

Contact Details

Proactive UK Ltd

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Latest news about Hemogenyx Pharmaceuticals Plc

EARNINGS: LSL starts 2024 "strongly"; Focusrite maintains payout	Apr. 25	AN
Hemogenyx Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25	CI
Hemogenyx Pharmaceuticals raises money for leukaemia treatment	Feb. 29	AN
Hemogenyx Pharmaceuticals Raises $4.2 Million via Share Placing	Feb. 29	MT
Hemogenyx Pharmaceuticals Achieves Breakthrough in Brain Cancer Treatment	Feb. 16	MT
Hemogenyx shares rise on potential for CBR to treat brain diseases	Feb. 16	AN
Hemogenyx Pharmaceuticals plc Announces CBR Brain Delivery	Feb. 16	CI
Hemogenyx Pharmaceuticals Tests Intranasal Delivery for Viral Infections Treatment	Feb. 14	MT
Hemogenyx says CBR can be used intranasally to treat viral infections	Feb. 14	AN
Hemogenyx shares surge as FDA lifts Hemo-Car-T trial hold	Feb. 09	AN
US FDA Removes Clinical Hold on Hemogenyx Pharmaceuticals' Acute Myeloid Leukemia Treatment	Feb. 09	MT
Hemogenyx Pharmaceuticals PLC Announces FDA Consents to Phase I Trials of HEMO-CAR-T	Feb. 09	CI
Hemogenyx Pharmaceuticals Obtains US Conditioning Patent	Feb. 02	MT
Hemogenyx hails US patent application progress	Feb. 02	AN
Hemogenyx Pharmaceuticals plc Announces Approval and Issuance of U.S. Conditioning Patent	Feb. 02	CI
Hemogenyx Pharmaceuticals sends complete response on HEMO-CAR-T to FDA	Jan. 16	AN
Hemogenyx Files Complete Response to US FDA's Clinical Hold of Leukemia Treatment Application	Jan. 16	MT
Hemogenyx Pharmaceuticals completes process qualification run	Jan. 08	AN
Hemogenyx Pharmaceuticals Wraps Up HEMO-CAR-T Process Qualification Run Following Clinical Hold	Jan. 08	MT
Hemogenyx Pharmaceuticals plc Announces Successful Completion of Its Process Qualification Run of the End-To-End Process for the Manufacture of HEMO-CAR-T Cells	Jan. 08	CI
Upland Resources completes technical study at Sarawak	Nov. 28	AN
Hemogenyx Platform Shows Potential for Blood Cancer Treatment; Shares Climb	Nov. 27	MT
Hemogenyx shares up as says CBR platform a potential cancer treatment	Nov. 27	AN
Hemogenyx Pharmaceuticals plc Announces CBR Expanded to Treatment of Cancer	Nov. 27	CI
Hemogenyx Pharmaceuticals completes lentivirus re-manufacture	Nov. 15	AN

Chart Hemogenyx Pharmaceuticals Plc

Duration

Period

More charts

Company Profile

Hemogenyx Pharmaceuticals plc is a preclinical-stage biotechnology company. The Company is focused on the discovery, development and commercialization of treatments relating to bone marrow/hematopoietic (blood-forming) stem cell (BM/HSC) transplants for blood diseases, including leukemia, lymphoma and bone marrow failure and viral infections. It is developing several distinct and complementary product candidates, as well as a platform technology. To obviate the use of chemotherapeutic agents for conditioning of patients undergoing BM/HSC transplantations, the Company developed a method of selective elimination of hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in patients using highly specific CDX antibodies. It has developed postnatal human hemogenic endothelial cells (Hu-PHEC cells) to generate cancer-free hematopoietic stem cells (HSC) for use in transplants to treat blood cancers. It has developed HEMO-CAR-T, for the potential treatment of acute myeloid leukemia (AML).

Sector

Biotechnology & Medical Research

Calendar

2024-09-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
HEMOGENYX PHARMACEUTICALS PLC	-28.26%	27.58M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs